ADL
FATE icon

Asset Dedication LLC’s Fate Therapeutics FATE Stock Holding History

Asset Dedication LLC’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-55
Closed – – 996
2023
Q4 		$0 Hold
55
– – ﹤0.01% 1003
2023
Q3 		$0 Hold
55
– – ﹤0.01% 1011
2023
Q2 		$0 Hold
55
– – ﹤0.01% 983
2023
Q1 		$0 Hold
55
– – ﹤0.01% 991
2022
Q4 		$1K Hold
55
– – ﹤0.01% 925
2022
Q3 		$1K Hold
55
– – ﹤0.01% 875
2022
Q2 		$1K Hold
55
– – ﹤0.01% 489
2022
Q1 		$2K Hold
55
– – ﹤0.01% 863
2021
Q4 		$3K Hold
55
– – ﹤0.01% 804
2021
Q3 		$3K Hold
55
– – ﹤0.01% 867
2021
Q2 		$5K Buy
+55
New +$4.43K ﹤0.01% 706

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Asset Dedication LLC's FATE Position: Q1 2024 in Review

Asset Dedication LLC sold out of Fate Therapeutics (FATE) in Q1 2024, closing a stake of 55 shares.

Asset Dedication LLC first reported a position in FATE in Q2 2021 and held it in 11 quarters. The position peaked at $5K in Q2 2021. 167 funds tracked by Wall St. Rank hold FATE as of Q1 2024.

  • Asset Dedication LLC reported no remaining Fate Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Asset Dedication LLC sold 55 Fate Therapeutics shares in Q1 2024.
  • Asset Dedication LLC first reported a position in Fate Therapeutics in Q2 2021 and held it in 11 quarters.
  • Asset Dedication LLC's Fate Therapeutics position peaked at $5K in Q2 2021.
  • 167 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2024.

Based on Asset Dedication LLC's 13F filing for Q1 2024, filed 16 Apr 2024.